Allarity Therapeutics (ALLR) News Today $1.58 +0.11 (+7.48%) Closing price 09/18/2025 04:00 PM EasternExtended Trading$1.58 +0.00 (+0.32%) As of 09/18/2025 07:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ALLR Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 Time Period Allarity Therapeutics CEO Thomas Jensen to Present at Biomarkers & Precision Medicine 2025 ConferenceSeptember 17 at 8:30 AM | quiverquant.comQAllarity Therapeutics CEO to Present at Biomarkers & Precision Medicine 2025September 17 at 8:00 AM | globenewswire.comShort Interest in Allarity Therapeutics, Inc. (NASDAQ:ALLR) Increases By 495.8%September 13, 2025 | americanbankingnews.comAllarity Therapeutics’ Stenoparib Receives FDA Fast TrackAugust 29, 2025 | msn.comAllarity Therapeutics Wins FDA Fast Track Designation for Ovarian Cancer Drug Candidate StenoparibAugust 27, 2025 | msn.comAllarity Therapeutics stock soars after FDA Fast Track designationAugust 26, 2025 | investing.comWhy Did Allarity Therapeutics Stock Double In Value Today?August 26, 2025 | msn.comWhy Is Allarity Therapeutics Stock (ALLR) Up 95% Today?August 26, 2025 | msn.comAllarity Therapeutics shares pop as ovarian cancer therapy recieves FDA Fast Track DesignationAugust 26, 2025 | proactiveinvestors.comAllarity Therapeutics Granted FDA Fast Track Designation for Stenoparib for the Treatment of Advanced Ovarian CancerAugust 26, 2025 | globenewswire.comAllarity Therapeutics Provides Second Quarter 2025 Update, Highlighting Clinical Progress, IP Expansion, and New PartnershipsAugust 15, 2025 | globenewswire.comAllarity Therapeutics Delays 10-Q FilingAugust 15, 2025 | msn.comAscendiant Capital Initiates Coverage of Allarity Therapeutics (ALLR) with Buy RecommendationJuly 28, 2025 | msn.comAllarity Therapeutics, Inc.: Allarity Therapeutics Announces New Licensing and Laboratory Services Agreement to Expand DRP Platform UtilizationJuly 15, 2025 | finanznachrichten.deAllarity Therapeutics Announces New Licensing and Laboratory Services Agreement to Expand DRP® Platform UtilizationJuly 15, 2025 | finance.yahoo.comAllarity Therapeutics Announces New Licensing and Laboratory Services Agreement to Expand DRP® Platform UtilizationJuly 15, 2025 | globenewswire.comAllarity Therapeutics Announces Appointment of Jeff Ervin as Chief ...July 9, 2025 | seekingalpha.comAllarity Therapeutics Appoints Jeff Ervin as New Chief Financial OfficerJuly 9, 2025 | nasdaq.comAllarity Therapeutics, Inc.: Allarity Therapeutics Announces Appointment of Jeff Ervin as Chief Financial OfficerJuly 8, 2025 | finanznachrichten.deAllarity Therapeutics Announces Appointment of Jeff Ervin as Chief Financial OfficerJuly 7, 2025 | globenewswire.comAllarity Therapeutics, Inc.: Allarity Therapeutics Receives Australian Patent Acceptance Notice for Stenoparib DRP Companion Diagnostic - FinanzNachrichten.deJuly 2, 2025 | finanznachrichten.deAllarity Therapeutics Announces Acceptance of Patent Application for Stenoparib DRP® in Australia - NasdaqJuly 2, 2025 | nasdaq.comAllarity Therapeutics Receives Australian Patent Acceptance Notice for Stenoparib DRP® Companion DiagnosticJune 30, 2025 | finance.yahoo.comAllarity Therapeutics Doses Second Patient in Phase 2 Trial of Stenoparib for Ovarian Cancer - NasdaqJune 29, 2025 | nasdaq.comAllarity Therapeutics, Inc.: Allarity Therapeutics Announces Dosing of Second Patient in New Phase 2 Trial of Stenoparib in Advanced Ovarian CancerJune 27, 2025 | finanznachrichten.deAllarity Therapeutics Announces Dosing of Second Patient in New Phase 2 Trial of Stenoparib in Advanced Ovarian CancerJune 27, 2025 | globenewswire.comAllarity Therapeutics Appoints Jesper Høiland to Board of Directors, Succeeding Joseph VazzanoJune 13, 2025 | nasdaq.comAllarity Therapeutics Announces Changes to Board of DirectorsJune 11, 2025 | globenewswire.comAllarity announces first patient enrolled in Phase 2 trial of stenoparibJune 2, 2025 | msn.comAllarity Therapeutics Announces First Patient Enrolled in New Phase 2 Clinical Trial Protocol of Stenoparib in Advanced Ovarian CancerJune 2, 2025 | finance.yahoo.comAllarity Therapeutics Provides First Quarter 2025 Update, Highlighting Continued Stenoparib Benefit and Upcoming Trial EnrollmentMay 9, 2025 | globenewswire.comAllarity unveils new multiple myeloma treatment predictorApril 26, 2025 | investing.comAllarity Therapeutics Presents Novel Drug Response Predictor—DRP®—for Daratumumab in Multiple Myeloma at AACR 2025April 26, 2025 | finance.yahoo.comAllarity Therapeutics Restructures Board of DirectorsApril 16, 2025 | tipranks.comALLR Shareholders are Encouraged to Join Allarity Therapeutics, Inc. ...April 14, 2025 | gurufocus.comALLR Shareholders are Encouraged to Join Allarity Therapeutics, Inc. Securities Fraud Investigation with the Schall Law FirmApril 14, 2025 | prnewswire.comAllarity Therapeutics, Inc.: Allarity Therapeutics Reports Full Year 2024 Financial Results and Provides a Business UpdateApril 2, 2025 | finanznachrichten.deAllarity Therapeutics Reports Full Year 2024 Financial Results and Provides a Business UpdateMarch 31, 2025 | markets.businessinsider.comAllarity Therapeutics probes potential stock manipulationMarch 26, 2025 | uk.investing.comALLR Shareholders are Encouraged to Join Allarity Therapeutics, Inc. Securities Fraud Investigation with the Schall Law FirmMarch 25, 2025 | prnewswire.comAllarity launches effort to combat potential illegal naked short sellingMarch 24, 2025 | markets.businessinsider.comAllarity Therapeutics Launches Comprehensive Effort to Combat Potential Illegal Naked Short Selling of Its SharesMarch 24, 2025 | markets.businessinsider.comALLR Shareholders are Encouraged to Join Allarity Therapeutics, Inc. Securities Fraud Investigation with the Schall Law FirmMarch 19, 2025 | prnewswire.comAllarity announces presentation from Phase 2 trial with stenoparib monotherapyMarch 17, 2025 | markets.businessinsider.comALLR Investors Have Opportunity to Join Allarity Therapeutics, Inc. Securities Fraud Investigation with the Schall Law FirmMarch 14, 2025 | prnewswire.comAllarity Therapeutics, Inc.: Allarity Therapeutics Announces Final Settlement with the U.S. Securities and Exchange CommissionMarch 14, 2025 | finanznachrichten.deAllarity sees cash runway into 2026March 14, 2025 | markets.businessinsider.comAllarity announces final settlement with SEC including $2.5M civil penaltyMarch 13, 2025 | markets.businessinsider.comAllarity Therapeutics Announces Final Settlement with the U.S. Securities and Exchange CommissionMarch 13, 2025 | globenewswire.comAllarity announes Phase 2 trial of stenoparib with temozolomideMarch 6, 2025 | markets.businessinsider.com Get Allarity Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ALLR and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ALLR Media Mentions By Week ALLR Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ALLR News Sentiment▼0.490.63▲Average Medical News Sentiment ALLR News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ALLR Articles This Week▼33▲ALLR Articles Average Week Get the Latest News and Ratings for ALLR and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Allarity Therapeutics and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies Biomea Fusion News Pliant Therapeutics News Equillium News InflaRx News VistaGen Therapeutics News TScan Therapeutics News Oncolytics Biotech News HilleVax News Coya Therapeutics News Surrozen News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ALLR) was last updated on 9/19/2025 by MarketBeat.com Staff From Our PartnersHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredStrange crypto pattern discovered by 40-person research teamSomething unusual is happening inside a 40-person crypto research firm. They're helping 8,000+ ordinary peo...Crypto Swap Profits | SponsoredThis is the “End of Tesla” as we know it…Jeff has identified five of the past seven number-one performing tech stocks — before they took off. His Tesla...Brownstone Research | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Allarity Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Allarity Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
